Opioid use disorder

Psychiatry· 6 reviewed drugs· 2951 cited findings behind them

What the regulatory reviews cover

This page provides an overview of drugs for which regulatory review documents related to opioid use disorder are available in this library. These include CAM2038, Lucemyra, Buvidal, and Sublocade. It is important to note that these drugs were studied in different trials, and therefore, the reported figures are not directly comparable head-to-head.

For CAM2038, non-inferiority versus SL BPN/NX was observed with a p-value of 0.001. Lucemyra demonstrated a SOWS-Gossop completer rate versus placebo at Day 5 (2.4 mg/day) of 46%. Buvidal showed an overall median cumulative percent urine samples negative for illicit opioids (CAM2038) of 26.7%. Sublocade reported a treatment success rate (responder) of 28%-29% versus placebo at 2%.

The drugs — one cited result each

CAM2038 Braeburn	Non-inferiority of CAM2038 vs SL BPN/NX: p = 0.001 Braeburn — Brixadi FDA Review (NDA210136, ORIG 1, 2023), p.14
Lybalvi Alkermes plc	669 cited findings on the drug page →
Lucemyra BIOCORRX PHARMS	SOWS-Gossop completer rate vs placebo at Day 5 (2.4 mg/day): 46% BIOCORRX PHARMS — Lucemyra FDA Review (NDA209229, ORIG 1, 20, p.331
Buvidal Camurus	overall median cumulative percent urine samples negative for illicit opioids (CAM2038): 26.7% Camurus — Buvidal EMA EPAR public assessment report (EMEA/H/, p.77
Sublocade Indivior PLC	Treatment success rate (responder) vs placebo: 2% Indivior PLC — Sublocade FDA Review (NDA209819, ORIG 1, 2017, p.12
Zubsolv Accord S L U	63 cited findings on the drug page →

Different drugs were studied in different trials — these figures are not head-to-head comparisons.

Explore the full evidence

Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Psychiatry research library →

Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.